ArticleFrontiers in oncology2021
Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- Rethinking gastroenteropancreatic neuroendocrine neoplasms: A perspective on cellular origins, molecular mechanisms, and combination therapies.Journal of translational internal medicine · 2026Article
- Rectal neuroendocrine tumors in a Latin American population: Insights from a Peruvian national cancer institute.World journal of gastrointestinal oncology · 2025Article
- Gender-based differences in survival outcomes of rectal neuroendocrine tumors: a population-based analysis.Discover oncology · 2025Article
- Lymph node metastasis of grade 1 neuroendocrine tumor from rectal mixed neuroendocrine non-neuroendocrine neoplasm: A case report.The Journal of international medical research · 2025Article
- Current status of endoscopic resection for small rectal neuroendocrine tumors.World journal of gastroenterology · 2025Review
- Comparison of clinicopathological characteristics and survival outcomes between solitary and multiple rectal neuroendocrine tumors: a propensity score-matched study.Frontiers in oncology · 2025Article
- Treatment indicators and prognostic factors in colorectal neuroendocrine neoplasms and adenocarcinoma with neuroendocrine differentiation: a single center retrospective study.International journal of colorectal disease · 2024Article
- Laparoscopic versus open surgery for rectal neuroendocrine tumors: a multicenter real-world study.BMC cancer · 2024Article
- GATIS score for predicting the prognosis of rectal neuroendocrine neoplasms: A Chinese multicenter study of 12-year experience.World journal of gastroenterology · 2024Article
- Impact of grade on workup of rectal neuroendocrine tumors: a retrospective cohort study : Grade impact on workup of rectal NETs.World journal of surgical oncology · 2024Article
- Simultaneous rectal neuroendocrine tumors and pituitary adenoma: A case report and review of literature.World journal of gastroenterology · 2023Review
- Risk Factors and Clinical Outcomes of 54 Cases of Rectal Neuroendocrine Tumors with Incomplete Resection: A Retrospective Single-Center Study.Therapeutics and clinical risk management · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare clinicopathologic feature of rectal neuroendocrine tumor (NET) grade G1 with G2 NET.
methodsSix hundred-one cases of rectal G1 and G2 NETs diagnosed in our center were analyzed.
resultsOf 601 cases of rectal NET, 515 cases were with grade G1 and 86 cases were with grade G2. Median tumor size was 0.7 cm. Compared with G1 NET, G2 tumors were with significantly larger tumor size (0.8 vs 2.2 cm, p < 0.001), less percentages of patients with tumors confined to submucosa (92.6 vs 42.8%, p < 0.001), more frequent presence of microvascular invasion (MVI) (3.6 vs 16.9%, p < 0.001) or peri-neural invasion (PNI) (2.0 vs 24.1%, p < 0.001). Incidence of lymph node and distant metastasis was 5.2 and 2.1% in G1 NET compared with 44.2 and 31.4% in G2 tumor, respectively (p < 0.001). For tumors sized 1-2 cm and confined to submucosa, incidence of lymph node metastasis was 6.1% for G1 NET compared with 21.1% for G2 NET. Status of MVI/PNI was predictive of lymph node metastasis for G2 tumor rather than G1 NET in this subgroup.
conclusionsRectal G2 NET was much more invasive with significantly elevated prevalence of lymph node metastasis compared with G1 tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.